Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELDNNASDAQ:GNFTNASDAQ:NGNENASDAQ:ZIVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$3.24-3.6%$3.50$1.91▼$5.54$194.02M0.66285,205 shs89,614 shsGNFTGenfit$3.64-0.8%$3.50$2.55▼$6.42$181.99M1.2214,685 shs3,067 shsNGNENeurogene$15.41+0.3%$13.98$6.88▼$74.49$230.07M1.46228,523 shs143,530 shsZIVOZIVO Bioscience$18.80+5.9%$17.53$3.13▼$22.15$71.28M-0.09985 shs401 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals0.00%+12.37%-3.17%-24.15%+70.56%GNFTGenfit+0.80%+5.31%+7.62%+3.23%+6.53%NGNENeurogene-0.45%+33.77%+8.24%+2.06%-49.16%ZIVOZIVO Bioscience+11.00%+11.00%+3.86%-5.91%+122.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals2.0445 of 5 stars3.52.00.00.03.21.70.0GNFTGenfit1.1228 of 5 stars3.53.00.00.00.00.00.0NGNENeurogene2.2373 of 5 stars3.61.00.00.03.51.70.6ZIVOZIVO BioscienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals 3.00Buy$12.50285.80% UpsideGNFTGenfit 3.00Buy$13.00257.14% UpsideNGNENeurogene 3.13Buy$47.20206.29% UpsideZIVOZIVO Bioscience 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest ZIVO, NGNE, GNFT, and ELDN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/14/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$45.00 ➝ $16.003/25/2025NGNENeurogeneRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$38.003/25/2025NGNENeurogeneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/25/2025NGNENeurogeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $50.002/7/2025GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.001/28/2025ELDNEledon PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$9.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$0.30 per shareN/AGNFTGenfit$76.06M2.39N/AN/A$1.48 per share2.46NGNENeurogene$925K248.73N/AN/A$14.51 per share1.06ZIVOZIVO Bioscience$15.85K4,497.35N/AN/A($0.81) per share-23.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$116.54M-$2.36N/AN/AN/AN/A-189.99%-28.17%5/8/2025 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/AN/ANGNENeurogene-$36.32M-$4.27N/AN/AN/AN/A-32.81%-27.96%5/9/2025 (Estimated)ZIVOZIVO Bioscience-$7.78M-$4.28N/A∞N/AN/AN/A-2,240.92%5/12/2025 (Estimated)Latest ZIVO, NGNE, GNFT, and ELDN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NGNENeurogene-$1.05N/AN/AN/AN/AN/A5/8/2025Q1 2025ELDNEledon Pharmaceuticals-$0.28N/AN/AN/AN/AN/A3/24/2025Q4 2024NGNENeurogene-$1.04-$0.99+$0.05-$0.99N/A$0.93 million3/20/2025Q4 2024ELDNEledon Pharmaceuticals-$0.32-$0.64-$0.32-$0.64N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/AZIVOZIVO BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A6.536.53GNFTGenfit0.613.743.74NGNENeurogeneN/A9.099.09ZIVOZIVO BioscienceN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%GNFTGenfit2.24%NGNENeurogene52.37%ZIVOZIVO Bioscience12.83%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals11.70%GNFTGenfit4.20%NGNENeurogene9.92%ZIVOZIVO Bioscience21.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1059.88 million52.75 millionOptionableGNFTGenfit12050.00 million47.90 millionNot OptionableNGNENeurogene9014.93 million13.38 millionOptionableZIVOZIVO Bioscience103.79 million2.91 millionNot OptionableZIVO, NGNE, GNFT, and ELDN HeadlinesRecent News About These CompaniesZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in PoultryFebruary 6, 2025 | businesswire.comZivo Bioscience issues new shares, raises $1.5 millionJanuary 28, 2025 | msn.comTuesday's Insider Activity: Top Buys and Sells in US Stocks RevealedJanuary 1, 2025 | investing.comZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian InfluenzaDecember 20, 2024 | businesswire.comZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023March 18, 2024 | investorplace.comHarmony Biosciences HoldingsMarch 4, 2024 | forbes.comRegencell Bioscience Holdings Ltd RGCFebruary 1, 2024 | morningstar.comZIVO Bioscience Announces Uplisting to OTCQB MarketJanuary 29, 2024 | finance.yahoo.comIdeaya BiosciencesJanuary 18, 2024 | forbes.comDare Bioscience Inc DAREJanuary 14, 2024 | morningstar.comZivo Bioscience Inc (ZIVO) USD0.001November 11, 2023 | hl.co.ukZivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72November 2, 2023 | msn.comZivo Bioscience Inc ZIVONovember 1, 2023 | morningstar.comZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler ChickensOctober 30, 2023 | finance.yahoo.comZivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain ComplianceOctober 26, 2023 | markets.businessinsider.comZivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rulesOctober 26, 2023 | msn.comAdam Zivo: Nazi veteran’s memoir lays bare the pitfalls of nationalismOctober 5, 2023 | nationalpost.comZIVO Bioscience to Present at the Dawson James Small Cap Growth ConferenceOctober 3, 2023 | finance.yahoo.comAdam Zivo: The sad truth about socialist 'anti-imperialists' who defend PutinSeptember 26, 2023 | nationalpost.comTrial Results Confirm Efficacy of ZIVO Bioscience’s Non-Antibiotic Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler ChickensSeptember 19, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZIVO, NGNE, GNFT, and ELDN Company DescriptionsEledon Pharmaceuticals NASDAQ:ELDN$3.24 -0.12 (-3.57%) Closing price 04:00 PM EasternExtended Trading$3.26 +0.01 (+0.46%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Genfit NASDAQ:GNFT$3.68 +0.01 (+0.30%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Neurogene NASDAQ:NGNE$15.41 +0.04 (+0.26%) Closing price 04:00 PM EasternExtended Trading$14.93 -0.48 (-3.09%) As of 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.ZIVO Bioscience NASDAQ:ZIVO$18.80 +1.04 (+5.87%) As of 01:47 PM EasternZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
